Amneal Pharmaceuticals reported third-quarter net revenue of $863 million, a 10% increase year-over-year, alongside an adjusted diluted EPS of $0.26. The company raised its full-year 2026 guidance for net revenue to $3.15 billion–$3.25 billion and adjusted EBITDA to $800 million–$815 million. GAAP results included a net loss of $22 million due to acquisition costs related to the Kashiv BioSciences deal and legal charges, while adjusted EBITDA rose 30% to $207 million. Amneal Pharmaceuticals is a diversified global biopharmaceutical company focused on affordable generics, specialty medicines, and biosimilars.
